Pharmaceuticals News and Research

RSS

FDA issues complete response letter regarding the NDA for OMAPRO

ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

12 Apr 2010

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010

Scientists discover and block pathway responsible for link between stress, anxiety and depression

Scientists at The University of Western Ontario have discovered the biological link between stress, anxiety and depression. By identifying the connecting mechanism in the brain, this high impact research led by Stephen Ferguson of Robarts Research Institute shows exactly how stress and anxiety could lead to depression.

12 Apr 2010

IMAGE project to be launched for prevention of type 2 diabetes

Researchers and clinicians from across the UK have been part of a pan-European team that has developed the first Europe wide strategy for the prevention of type 2 diabetes. The project received substantial funding of -1.2 million from the European Union.

9 Apr 2010

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Catalyst Pharmaceutical Partners, Inc. today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence"

9 Apr 2010

Cephalon acquires Mepha

Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.

9 Apr 2010

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

Penwest Pharmaceuticals Co. today announced that it has signed a drug development and commercialization agreement with Alvogen, Inc. under which Penwest and Alvogen have agreed to identify and select up to five compounds for generic development. Penwest's TIMERx technology may be used for each compound selected.

9 Apr 2010

More public-private partnerships crucial for success of Italian pharmaceutical industry

The newly retired Chief Executive Officer of Roche Pharmaceuticals Bill Burns today led calls for more public-private partnerships in the pharmaceutical industry at the launch of the Italian Institute of Technology's Drug Discovery and Development Unit (D3).

9 Apr 2010

ONA supports government's concern about rising costs of pharmaceuticals

Noting that Ontario already spends 10.7 per cent more on drugs per capita than other provinces, the Ontario Nurses' Association is pleased that the government is turning its attention to reducing provincial drug costs.

9 Apr 2010

Investment report on Radient Pharmaceuticals from StockPreacher.com

StockPreacher.com announces an investment report featuring Radient Pharmaceuticals Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Labopharm: Investment report

StockPreacher.com announces an investment report featuring Labopharm Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Investment report on Somaxon Pharmaceuticals

StockPreacher.com announces an investment report featuring Somaxon Pharmaceuticals, Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

BeaconEquity.com announces an investment report featuring Avanir Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

HemCon Medical Technologies, Inc., an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with Zeria Pharmaceuticals Co. Ltd., a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon's line of revolutionary wound and oral care dressings throughout Japan.

9 Apr 2010

PAREXEL International experts to present key industry topics during conference in Orlando

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will present key industry topics during the 19th Annual Partnerships in Clinical Trials Conference, to be held April 12 – 14, 2010 in Orlando, Florida.

From Parexel 9 Apr 2010

Wolters Kluwer Health agrees to provide access to Martindale: The Complete Drug Reference

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, has announced an agreement to provide access to Martindale: The Complete Drug Reference as part of premium subscriptions to its flagship drug reference, Facts & Comparisons® eAnswers.

9 Apr 2010

Ten loopholes and problem areas in new federal health reform law

Consumer Watchdog called on President Obama and Congress in a letter sent today to fix ten problem areas in the new federal health reform law that, if not addressed, will be exploited by health insurers and drug companies looking to charge more for less health care.

9 Apr 2010

Scientists join USP to foster global harmonization of standards for medicines, food ingredients

To promote international scientific exchange and ultimately foster global harmonization of standards for medicines and food ingredients, scientists from around the world will join the U.S. Pharmacopeial Convention at its headquarters on a rolling basis throughout 2010.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Pfizer to expand clinical trials in Asia, work on development of antibiotics for drug-resistant TB

The pharmaceutical company Pfizer said on Wednesday that it plans to increase the number of clinical trials it's conducting in Singapore by 10 percent as part of an effort "to design drugs for diseases prevalent in the region," Reuters reports.

9 Apr 2010

Pharmaceuticals News and Research

FDA issues complete response letter regarding the NDA for OMAPRO

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Scientists discover and block pathway responsible for link between stress, anxiety and depression

IMAGE project to be launched for prevention of type 2 diabetes

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Cephalon acquires Mepha

Penwest Pharmaceuticals signs drug development and commercialization agreement with Alvogen

More public-private partnerships crucial for success of Italian pharmaceutical industry

ONA supports government's concern about rising costs of pharmaceuticals

Investment report on Radient Pharmaceuticals from StockPreacher.com

Labopharm: Investment report

Investment report on Somaxon Pharmaceuticals

BeaconEquity.com announces investment report featuring Avanir Pharmaceuticals

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

PAREXEL International experts to present key industry topics during conference in Orlando

Wolters Kluwer Health agrees to provide access to Martindale: The Complete Drug Reference

Ten loopholes and problem areas in new federal health reform law

Scientists join USP to foster global harmonization of standards for medicines, food ingredients

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Pfizer to expand clinical trials in Asia, work on development of antibiotics for drug-resistant TB

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence